Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting

被引：0

作者：

Shanshan Hu

Yilai Wu

Jiajie Luan

Shuowen Wang

Guorong Fan

机构：

[1] Shanghai General Hospital,Department of Clinical Pharmacy

[2] Shanghai Jiao Tong University School of Medicine,Department of Pharmacy

[3] The First Affiliated Hospital of Wannan Medical College,undefined

来源：

Journal of Cancer Research and Clinical Oncology | 2023年 / 149卷

关键词：

Cost–utility analysis; HER2-positive metastatic breast; Trastuzumab deruxtecan; Trastuzumab emtansine; Price exploring;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：17933 / 17942

页数：9

共 214 条

[91]

Jiang Z(undefined)undefined undefined undefined undefined-undefined

[92]

Li J(undefined)undefined undefined undefined undefined-undefined

[93]

Chen J(undefined)undefined undefined undefined undefined-undefined

[94]

Liu Y(undefined)undefined undefined undefined undefined-undefined

[95]

Wang K(undefined)undefined undefined undefined undefined-undefined

[96]

Nie J(undefined)undefined undefined undefined undefined-undefined

[97]

Wang X(undefined)undefined undefined undefined undefined-undefined

[98]

Hao C(undefined)undefined undefined undefined undefined-undefined

[99]

Yin Y(undefined)undefined undefined undefined undefined-undefined

[100]

Wang S(undefined)undefined undefined undefined undefined-undefined